In 2020, the world was tested in ways we could never have imagined. The COVID-19 pandemic has had a devastating impact across the globe and yet it has also demonstrated our strength, our resilience and our ability to overcome great challenges. We have been reminded of what is most important, and of how much we are capable of achieving when we pull together.
Even under the best circumstances, logistics requires precision and adaptability to be successful. Factor in a cargo of live patient cells, and things become even more critical. A year ago in March, as the pandemic took hold across Europe, severe travel restrictions were implemented – increasing these challenges.
As conversations about racial equity began across the United States and around the world last summer following the killing of George Floyd, Gilead’s Leadership Team started a dialogue with the company’s Black employees.
In the latest episode of our ongoing “Possible” series, meet Valerie Brown, Senior Vice President of Quality Assurance and the Executive Sponsor of the GLOBE employee resource group. Hear Valerie discuss that dialogue and share why she is optimistic about the future as the company works to evolve its culture to be more inclusive.
As COVID-19 began to spread around the world, Gilead employees worked around the clock to advance the company’s investigational antiviral.
In the next episode of our “Possible” series, meet Laura Bauer, a scientist in the company’s Formulation and Process Development group. Learn how she worked with her team, colleagues at Gilead, and partners across a wide manufacturing and supply chain network to expand production.
Gilead and the Satcher Health Leadership Institute at Morehouse School of Medicine announced a new partnership to develop a real-time, public-facing and comprehensive health equity data platform to help address the impact of COVID-19 and other diseases on communities of color.
Throughout my education and during the first decade of my career as a clinical pharmacologist, I carried a huge burden. Around classmates and colleagues, I held a secret about who I really was – I was in the closet.
I hid this part of my identity because, like many LGBTQ+ individuals, I feared that my sexual orientation would limit or even jeopardize my career. When I began my scientific training, I didn’t have any openly gay role models to consult or rely upon. Without a well-defined path forward, it made me question what my future in science would be.
After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital.
By John Sayre, Senior Vice President of Development Operations at Gilead
When I was in college, I learned about the Spanish Flu in a class on the history of medicine. I found the pandemic so fascinating that I reached out to my grandmother Cordelia to ask her about it. She was about 80 by then but still remembered it vividly. She described driving through a neighborhood in Akron, Ohio at the age of 15 and seeing people throwing furniture out of an attic window. Everyone in the house had died, and they were burning everything inside to kill the germs.